Accessibility Menu
Xeris Biopharma logo

Xeris Biopharma

(NASDAQ) XERS

Current Price$8.84
Market Cap$1.50BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2021)+268%
5 Year+151%
1 Year+65%
1 Month+26%
Xeris Biopharma last closing stock price
MetricPriceDate
Last closeUSD 8.692026-07-16
Xeris Biopharma stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+0.81%USD 8.622026-07-09
1 month+25.94%USD 6.902026-06-16
3 month+36.42%USD 6.372026-04-17
Year to date+10.7%USD 7.852025-12-31
1 year+65.21%USD 5.262025-07-16
3 year+236.82%USD 2.582023-07-17
5 year+151.16%USD 3.462021-07-16
Since inception+268.22%USD 2.362021-10-06

Xeris Biopharma Financials at a Glance

Market Cap

$1.50BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$314.85M

Net Income (TTM)

$12.01M

EPS (TTM)

$0.07

P/E Ratio

132.67

Dividend

$0.00

Beta (Volatility)

1.26 (Average)

Price

$8.84

Volume

40,949

Open

$8.50

Previous Close

$8.69

Daily Range

$8.50 - $8.99

52-Week Range

$4.87 - $10.08

Estimated Earnings Date

Aug 6, 2026

XERS News

Two people in white lab coats looking at a computer display

Why Xeris Biopharma Stock Zoomed 7% Higher on Wednesday

Eric VolkmanDec 31, 2025
Foolcom-Featured.png

Xeris (XERS) Q2 Revenue Jumps 49%

Motley Fool Markets TeamAug 7, 2025

XERS: Motley Fool Moneyball Superscore

69

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Xeris Biopharma

Xeris Biopharma makes ready-to-use medicines for people with chronic diseases. Its products help patients manage serious hormonal and neurological conditions. These treatments are designed to be simpler and easier to use.

What is in the Bag?

  • Recorlev: Oral medication used to treat adults with Cushing syndrome, a rare condition caused by high levels of the hormone cortisol.
  • Gvoke: Liquid glucagon used to treat very low blood sugar emergencies in people with diabetes.
  • Keveyis: First approved therapy for primary periodic paralysis, a rare disorder that causes muscle weakness or paralysis.
  • Technology Platforms: Licensed systems called XeriSol and XeriJect that help other companies make their drugs stable and easy to inject.

Strategic Moves and New Tech

  • Acquired Strongbridge Biopharma plc to add rare disease treatments to its commercial lineup.
  • Completed a meeting with the FDA in late 2024 to discuss final testing for a weekly thyroid treatment.
  • Partnered with other pharmaceutical firms to use its formulation science on new biologics and small molecules.

The Science of Staying Dry

Xeris uses specialized technology to create stable, water-free liquid versions of drugs. This allows for small injections that do not need mixing or refrigeration before use.

By the Numbers

  • Revenue hit $85.8 million in Q4 2025, up 42.8% year-over-year.
  • Net income reached $11.1 million in Q4 2025, up 316.7% from Q4 2024 (turned positive — improved).
  • Operating income grew to $16.8 million in Q4 2025, up 899% from $1.7 million in Q4 2024.
  • Free cash flow reached $19.7 million in Q4 2025, up 1023.1% from Q4 2024.

The Bottom Line

Xeris has transitioned from a research firm into a commercial company with three approved therapies. Its growth depends on finding more patients for its current drugs and developing its weekly thyroid injection.

AI Generated • May 2, 2026

Industry

Pharmaceuticals

Sector

Health Care

Employees

435

CEO

John Patrick Shannon, Jr.

Website

www.xerispharma.com

Headquarters

Chicago, IL 60601, US

XERS Financials

Key Financial Metrics (TTM)

Gross Margin

81.59%

Operating Margin

11.40%

Net Income Margin

3.81%

Return on Equity

735.00%

Return on Capital

48.39%

Return on Assets

3.06%

Earnings Yield

0.75%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$1.50BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

172.64M

Volume

40.95K

Avg. Volume

1.88M

Financials (TTM)

Gross Profit

$256.89M

Operating Income

$35.90M

EBITDA

$46.13M

Operating Cash Flow

$48.53M

Capital Expenditure

-$1.30M

Free Cash Flow

$47.23M

Cash & ST Invst.

$111.75M

Total Debt

$37.33M

Xeris Biopharma Performance Analysis

Xeris Biopharma annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 110,248,000122.3%
20232023-12-31USD 163,914,00048.7%
20242024-12-31USD 203,070,00023.9%
20252025-12-31USD 291,845,00043.7%
Xeris Biopharma sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-3019.0%
Q32025-09-304.0%
Q42025-12-3115.4%
Q12026-03-31-3.1%
Xeris Biopharma annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD -0.70-55.1%
20232023-12-31USD -0.45-35.2%
20242024-12-31USD -0.37-17.4%
20252025-12-31USD 0.00N/A
Xeris Biopharma sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-3080.0%
Q32025-09-30124.8%
Q42025-12-311950.0%
Q12026-03-31-79.5%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q1 2026YOY CHG

Revenue

$83.13M

+38.3%

Gross Profit

$69.84M

+35.9%

Gross Margin

84.02%

N/A

Market Cap

$1.50BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$3.45M

N/A

Employees

435

N/A

Net Income

$2.23M

+124.2%

EBITDA

$12.33M

+903.9%

Quarterly Fundamentals

Name
Q1 2026YOY CHG

Total Cash

$111.75M

+91.2%

Total Debt

$37.33M

-86.1%

Accounts Receivable

$56.30M

+21.5%

Inventory

$74.23M

+40.9%

Long Term Debt

$31.06M

-87.6%

Short Term Debt

$6.27M

-65.3%

Return on Assets

3.06%

N/A

Return on Invested Capital

13.13%

N/A

Free Cash Flow

$9.55M

+195.0%

Operating Cash Flow

$9.87M

+198.4%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
MAZEMaze Therapeutics, Inc.
$28.33+4.29%
BHVNBiohaven Ltd.
$15.30+7.97%
IMCRImmunocore Holdings plc
$35.02+1.59%
BCRXBioCryst Pharmaceuticals, Inc.
$9.19+0.89%

Trending Stocks

Symbol / CompanyPricePrice Chg
AALAmerican Airlines Group
$15.12-0.03%
TQQQProShares Trust - ProShares UltraPro Qqq
$69.42-0.02%
MUUDirexion Shares ETF Trust - Direxion Daily Mu Bull 2x Shares
$30.23+0.10%
PATHUiPath
$12.30+0.02%

Questions About XERS

What is the current price of Xeris Biopharma?

Xeris Biopharma is trading at $8.84 per share.

What is the 52-week range for Xeris Biopharma?

Over the past 52 weeks, Xeris Biopharma has traded between $4.87 and $10.08.

How much debt does Xeris Biopharma have?

As of the most recent reporting period, Xeris Biopharma reported total debt of $258.55M.

How much cash does Xeris Biopharma have on hand?

Xeris Biopharma reported $111.75M in cash and cash equivalents in its most recent financial results.

What is Xeris Biopharma’s dividend yield?

Xeris Biopharma does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services